PhRMA, MSF weigh in on drug patent case in India

01/23/2013 | Scienceline

The Indian Supreme Court is weighing the importance of protecting pharmaceutical innovation and providing affordable access to drugs after the country's generic-friendly patent law was challenged by a drugmaker's appeal concerning a cancer treatment. "The whole case is about encouraging generics and the central role they have had in treating deadly diseases," said Patricia Kahn of Medecins Sans Frontieres. Patents foster improved treatments, PhRMA's Mark Grayson said. "The kinds of tactics that MSF is taking will only end up hurting the people they are trying to help, because it could end up hurting innovation in areas where they would like to see more," Grayson said.

View Full Article in:


Published in Brief: